Synopsis

Source of validity: Scientific
Rating (out of 5): 2

β-Nicotinamide mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy metabolism and various biological processes. Scientific research has explored NMN’s effects on metabolic health, including its potential influence on pancreatic function, particularly in experimental models of metabolic disease. Preclinical studies in rodents have shown that NMN supplementation can enhance insulin secretion and sensitivity, likely through the restoration of NAD+ levels in pancreatic beta cells. NAD+ is critical for the function and survival of these cells, which are responsible for insulin production in the pancreas. Some studies have shown improved glucose tolerance and beta-cell function in NMN-treated animals. However, human clinical data directly linking NMN supplementation to improved pancreatic health or beta-cell function are limited. Most human studies to date focus on NMN’s effects on systemic NAD+ levels, metabolic parameters, and overall glucose metabolism, rather than specific pancreatic outcomes. There is currently insufficient evidence to conclusively state that NMN supplementation supports pancreas head body system health in humans. Thus, while scientific rationale and animal studies provide some support, the direct evidence in humans remains preliminary, justifying a moderate-low evidence rating.

More about β-nicotinamide mononucleotide (NMN)
More about Pancreas Head

Other ingredients that support Pancreas Head

Other body systems supported by β-nicotinamide mononucleotide (NMN)

Products containing β-nicotinamide mononucleotide (NMN)